Andrew Lindner

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares have lost 53 percent since September 23, declining steeply from a high of $223.99. CreditSights’ Andrew Lindner maintained an Outperform rating on the company. Despite Citron’s allegations of fraud at the company, it may not...